Retrospective evaluation of the short-term response of human intravenous immunoglobulin therapy in the management of canine immune-mediated thrombocytopenia (2010-2015): 27 cases.
ITP
canine
glucocorticoids
hIVIG
Journal
Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
ISSN: 1476-4431
Titre abrégé: J Vet Emerg Crit Care (San Antonio)
Pays: United States
ID NLM: 101152804
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
revised:
05
05
2023
received:
22
01
2022
accepted:
25
06
2023
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
aheadofprint
Résumé
To describe the short-term response, early prognostic markers, and survival after treatment of canine immune-mediated thrombocytopenia (ITP) with human intravenous immunoglobulin (hIVIG) and methylprednisolone. Retrospective cohort study. Private referral veterinary medical center. Twenty-seven client-owned dogs with primary or secondary ITP. All dogs received 2 mg/kg IV methylprednisolone once daily and a single infusion of 5% hIVIG administered over 6-12 hours. A substantial increase in platelet count within 60 ± 12 hours post-hIVIG infusion (T Responder dogs had an excellent 14-day survival rate. Serum T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Veterinary Emergency and Critical Care Society 2024.
Références
Lewis DC, Meyers KM. Canine idiopathic thrombocytopenic purpura. J Vet Intern Med. 1996;10(4):207‐218.
Crow AR, Song S, Siragam V, Lazarus AH. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer. 2006;47(5 Suppl):710‐713.
LeVine DN, Brooks MB. Immune thrombocytopenia (ITP): pathophysiology update and diagnostic dilemmas. Vet Clin Pathol. 2019;48(S1):17‐28.
Grindem CB, Breitschwerdt EB, Corbett WT, Page RL, Jans HE. Thrombocytopenia associated with neoplasia in dogs. J Vet Intern Med. 1994;8(6):400‐405.
Grindem CB, Breitschwerdt EB, Perkins P, Cullins L, Thomas T, Hegarty B. Platelet‐associated immunoglobulin (antiplatelet antibody) in canine Rocky Mountain spotted fever and ehrlichiosis. J Am Anim Hosp Assoc. 1999;35(1):56‐61.
Kohn B, Galke D, Beelitz P, Pfister K. Clinical features of canine granulocytic anaplasmosis in 18 naturally infected dogs. J Vet Intern Med. 2008;22(6):1289‐1295.
Axthelm MK, Krakowka S. Canine distemper virus‐induced thrombocytopenia. Am J Vet Res. 1987;48(8):1269‐1275.
Waner T, Harrus S, Weiss DJ, Bark H, Keysary A. Demonstration of serum antiplatelet antibodies in experimental acute canine ehrlichiosis. Vet Immunol Immunopathol. 1995;48(1–2):177‐182.
Handagama P, Feldman BF. Thrombocytopenia and drugs. Vet Clin North Am Small Anim Pract. 1988;18(1):51‐65.
McAnulty JF, Rudd RG. Thrombocytopenia associated with vaccination of a dog with a modified‐live paramyxovirus vaccine. J Am Vet Med Assoc. 1985;186(11):1217‐1219.
Huang AA, Moore GE, Scott‐Moncrieff JC. Idiopathic immune‐mediated thrombocytopenia and recent vaccination in dogs. J Vet Intern Med. 2012;26(1):142‐148.
Cummings FO, Rizzo SA. Treatment of presumptive primary immune‐mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs. J Small Anim Pract. 2017;58(2):96‐102.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386‐2393.
Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46(1 Suppl 2):S2‐S14.
Feldman BF, Handagama P, Lubberink AA. Splenectomy as adjunctive therapy for immune‐mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc. 1985;187(6):617‐619.
Vargo CL, Taylor SM, Haines DM. Immune mediated neutropenia and thrombocytopenia in 3 giant schnauzers. Can Vet J. 2007;48(11):1159‐1163.
Putsche JC, Kohn B. Primary immune‐mediated thrombocytopenia in 30 dogs (1997‐2003). J Am Anim Hosp Assoc. 2008;44(5):250‐257.
O'Marra SK, Delaforcade AM, Shaw SP. Treatment and predictors of outcome in dogs with immune‐mediated thrombocytopenia. J Am Vet Med Assoc. 2011;238(3):346‐352.
Williams DA, Maggio‐Price L. Canine idiopathic thrombocytopenia: clinical observations and long‐term follow‐up in 54 cases. J Am Vet Med Assoc. 1984;185(6):660‐663.
Bloom JC, Meunier LD, Thiem PA, Sellers TS. Use of danazol for treatment of corticosteroid‐resistant immune‐mediated thrombocytopenia in a dog. J Am Vet Med Assoc. 1989;194(1):76‐78.
Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune‐mediated conventional therapy. Transplant Proc. 1998;1345(98):4143‐4148.
Yau VK, Bianco D. Treatment of five haemodynamically stable dogs with immune‐mediated thrombocytopenia using mycophenolate mofetil as single agent. J Small Anim Pract. 2014;55(6):330‐333.
Kohn B, Bal G, Chirek A, Rehbein S, Salama A. Treatment of 5 dogs with immune‐mediated thrombocytopenia using Romiplostim. BMC Vet Res. 2016;12(1):96.
Horgan JE, Roberts BK, Schermerhorn T. Splenectomy as an adjunctive treatment for dogs with immune‐mediated hemolytic anemia: ten cases (2003‐2006): retrospective study. J Vet Emerg Crit Care. 2009;19(3):254‐261.
Rozanski EA, Callan MB, Hughes D, Sanders N, Giger U. Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune‐mediated thrombocytopenia in dogs. J Am Vet Med Assoc. 2002;220(4):477‐481.
Bianco D, Armstrong PJ, Washabau RJ. A prospective, randomized, double‐blinded, placebo‐controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune‐mediated thrombocytopenia in dogs. J Vet Intern Med. 2009;23(5):1071‐1078.
Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504‐522.
Bussel JB. Therapeutic approaches to secondary immune thrombocytopenic purpura. Semin Hematol. 2009;46(2 Suppl):S44‐S58.
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747‐755.
Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7:337‐342.
Samuelsson A. Anti‐inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291(5503):484‐486.
Sibley TA, Miller MM, Fogle JE. Human intravenous immunoglobulin (hIVIG) inhibits anti‐CD32 antibody binding to canine DH82 cells and canine monocytes in vitro. Vet Immunol Immunopathol. 2013;151(3–4):229‐234.
Audia S, Santegoets K, Laarhoven AG, et al. Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. Clin Exp Immunol. 2017;188(2):275‐282.
Nagelkerke SQ, Dekkers G, Kustiawan I, et al. Inhibition of FcγR‐mediated phagocytosis by IVIg is independent of IgG‐Fc sialylation and FcγRIIb in human macrophages. Blood. 2014;124(25):3709‐3718.
Bianco D, Armstrong PJ, Washabau RJ. Treatment of severe immune‐mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. J Vet Intern Med. 2007;21(4):694‐699.
Balog K, Huang AA, Sum S, Moore GE, Thompson C, Scott‐Moncrieff JC. A prospective randomized clinical trial of vincristine versus human intravenous immunoglobulin for acute adjunctive management of presumptive primary immune‐mediated thrombocytopenia in dogs. J Vet Intern Med. 2013;27:536‐541.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence‐based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190‐4207.
Garden OA, Kidd L, Mexas AM, et al. ACVIM consensus statement on the diagnosis of immune‐mediated hemolytic anemia in dogs and cats. J Vet Intern Med. 2019;33(2):313‐334.
Carli E, Tasca S, Trotta M, Furlanello T, Caldin M, Solano‐Gallego L. Detection of erythrocyte binding IgM and IgG by flow cytometry in sick dogs with Babesia canis canis or Babesia canis vogeli infection. Vet Parasitol. 2009;162(1–2):51‐57.
Wierenga JR, Jandrey KE, Haskins SC, Tablin F. In vitro comparison of the effects of two forms of hydroxyethyl starch solutions on platelet function in dogs. Am J Vet Res. 2007;68(6):605‐609.
Choi HS, Ji MH, Kim SJ, Ahn HS. Platelet count recovery after intravenous immunoglobulin predicts a favorable outcome in children with immune thrombocytopenia. Blood Res. 2016;51(2):95‐101.
Mason N, Duval D, Shofer FS, Giger U. Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune‐mediated hemolytic anemia in dogs: a randomized controlled clinical trial. J Vet Intern Med. 2003;17(2):206‐212.
Reimer ME, Troy GC, Warnick LD. Immune‐mediated hemolytic anemia: 70 cases (1988‐1996). J Am Anim Hosp Assoc. 1999;35(5):384‐391.
Klag A, Giger U, Shofer F. Idiopathic immune‐mediated hemolytic anemia in dogs: 42 cases (1986‐1990). J Am Vet Med Assoc. 1993;202(5):783‐788.
Piek CJ, Junius G, Dekker A, Schrauwen E, Slappendel RJ, Teske E. Idiopathic immune‐mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med. 2008;22(2):366‐373.
DeLong ER, DeLong DM, Clarke‐Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837‐845.
Stokol T, Brooks MB, Erb HN, Mauldin GE. D‐dimer concentrations in healthy dogs and dogs with disseminated intravascular coagulation. Am J Vet Res. 2000;61(4):393‐398.
Seifried E, Pindur G, Stötter H, Wiesneth M, Rasche H, Heimpel H. Treatment of refractory chronic idiopathic thrombocytopenic purpura with high dose intravenous immunoglobulin. Blut. 1984;48(6):369‐376.
Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol. 1999;107(4):716‐719.
Qin Y‐H, Zhou T‐B, Su L‐N, Lei F‐Y, Zhao Y‐J, Huang W‐F. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta‐analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis. 2010;21(8):713‐721.
Spurlock NK, Prittie JE. A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. J Vet Emerg Crit Care. 2011;21(5):471‐483.
Abelson AL, Shelton GD, Whelan MF, Cornejo L, Shaw S, O'Toole TE. Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs. J Vet Emerg Crit Care. 2009;19(4):369‐374.
Whelan MF, O'Toole TE, Chan DL, et al. Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune‐mediated hemolytic anemia: original study. J Vet Emerg Crit Care. 2009;19(2):158‐164.
Emmerich B, Hiller E, Woitinas F, et al. Dose‐response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin. Klin Wochenschr. 1987;65(8):369‐372.
Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227‐236.
Hong J, Bang SM, Mun YC, et al. Efficacy and safety of a new 10% intravenous immunoglobulin product in patients with primary immune thrombocytopenia (ITP). J Korean Med Sci. 2018;33(19):1‐13.
Scott‐Moncrieff JC, Treadwell NG, McCullough SM, Brooks MB. Hemostatic abnormalities in dogs with primary immune‐mediated hemolytic anemia. J Am Anim Hosp Assoc. 2001;37(3):220‐227.
Kellerman DL, Bruyette DS. Intravenous human immunoglobulin for the treatment of immune‐mediated hemolytic anemia in 13 dogs. J Vet Intern Med. 1997;11(6):327‐332.
Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547‐1554.
Sorenmo KU, Harwood LP, King LG, Drobatz KJ. Case‐control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy. J Am Vet Med Assoc. 2010;236(6):650‐656.
LaQuaglia KA, Robertson JB, Lunn KF. Neutropenia in dogs receiving vincristine for treatment of presumptive immune‐mediated thrombocytopenia. J Vet Intern Med. 2021;35(1):226‐233.
Lem KY, Fosgate GT, Norby B, Steiner JM. Associations between dietary factors and pancreatitis in dogs. J Am Vet Med Assoc. 2008;233(9):1425‐1431.
Orcutt ES, Lee JA, Bianco D. Immune‐mediated hemolytic anemia and severe thrombocytopenia in dogs: 12 cases (2001‐2008). J Vet Emerg Crit Care. 2010;20(3):338‐345.